A device assembly for producing bioconjugates, in particular antibody-drug conjugates, including a conjugation unit for performing a bioconjugation reaction in a medium, a first filtration unit for separating precipitates and/or agglomerates, and a second filtration unit for performing an ultrafiltration and/or a diafiltration process. The first filtration unit is arranged in a flow path between the conjugation unit and the second filtration unit. The device assembly further includes a single control unit for controlling the transfer of medium from the conjugation unit through the first filtration unit to the second filtration unit and for controlling the ultrafiltration and/or diafiltration process.

The present invention relates to systems and methods for filtration and/or dilution of fluids, in particular for the dialysis of blood. The systems comprise a filter device (10) having a fluid chamber (18) and comprising a first lid (20) having arranged thereon a first fluid port (22). The filter device (10) further comprises a second lid (30) having arranged thereon at least a second fluid port (32). The filter device (10) further comprises a plurality of hollow fibers (40) arranged within the housing (12), wherein each of the plurality of hollow fibers (40) comprises a semi-permeable membrane and defines a fluid channel extending longitudinally through an interior of the respective hollow fiber (40). Also, the filter device (10) comprises a fourth fluid port (50) and a fifth fluid port (52) both provided at the fluid chamber (18).

A blood treatment system and method controlling same are provided. The system comprises a blood pump for urging blood from an arterial or venous interface through a blood flow path; a dialyser in fluid communication with said blood flow path for ultrafiltering the blood to remove fluid therefrom; a fluid removal pump in fluid communication with said dialyser for urging ultrafiltered fluid away from said dialyser; a controller in signal communication with said blood pump; and a reversing valve for selectively reversing direction of blood flow in at least a portion of the blood flow path under signal control of said controller. The blood pump is selectively activatable under signal control of the controller.

A hemodialysis system is disclosed. The hemodialysis system includes a dialyzer, a saline container including saline, and a disposable set comprising a blood pumping tube fluidly connected to a first end of the dialyzer, an arterial line fluidly connected to a first end of the blood pumping tube, a venous line fluidly connected to a second end of the dialyzer, a saline line fluidly connected to the blood pumping tube and the saline container, and a dialyzer line fluidly connected to a second end of the blood pumping tube and a second end of the dialyzer. The hemodialysis system also includes a dialysis instrument comprising an arterial line clamp, a venous line clamp, and a saline valve. The saline rinses blood out of the arterial line when the venous line clamp is closed, the arterial line clamp is opened, and the saline value is opened.

A method for performing a peritoneal dialysis therapy includes performing a plurality of peritoneal dialysis cycles for a patient and tracking an amount of dialysis fluid provided by at least one dialysis fluid pump during the plurality of peritoneal dialysis cycles. The method also includes determining an amount of ultrafiltrate (“UF”) removed from the patient based on the amount of dialysis fluid provided by the at least one dialysis fluid pump. The method further includes updating a UF trend using previous amounts of UF removed from the patient and the amount of UF removed from the patient during the most recent dialysis treatment and generating an alert if the UF trend changes by more than a preset percentage.

A hemodialysis system is disclosed. The hemodialysis system includes a disposable set including a blood pumping tube, a fresh dialysate pumping tube, and a spent dialysate pumping tube. The hemodialysis system also includes a dialysis instrument including a blood pump head, a fresh dialysate pump head, a spent dialysate pump head, a first motor positioned and arranged to operate the blood pump head, a second motor positioned and arranged to operate the fresh dialysate pump head, and a third motor positioned and arranged to operate the spent dialysate pump head. When the disposable set is loaded into the dialysis instrument, the blood pumping tube comes into registry with the blood pump head, the fresh dialysate pumping tube comes into registry with the fresh dialysate pump head, and spent dialysate pumping tube comes into registry with the spent dialysate pump head.

A multilayer nano-cell includes an innermost water phase core including biomolecules in an aqueous solution; a first layer, including an oil phase layer encapsulating the innermost water phase core, thereby forming a water-in-oil structure, the oil phase layer including caprylic/capric triglyceride and macrogol-35-glycerol-rizinoleat; a second layer, including a water phase layer encapsulating the first layer, the water phase layer including hyaluronic acid, Cu-GHK tripeptide, palmitoyl-KTTKS pentapeptide, and hexapeptide argireline; a third layer, including another oil phase layer encapsulating the second layer; a fourth layer, including another water phase layer encapsulating the third layer; a fifth layer, including another oil phase layer encapsulating the fourth layer; and a sixth layer, including an outmost cream layer encapsulating the fifth layer.

A multilayer nano-cell includes an innermost water phase core including biomolecules in an aqueous solution; a first layer, including an oil phase layer encapsulating the innermost water phase core, thereby forming a water-in-oil structure, the oil phase layer including caprylic/capric triglyceride and macrogol-35-glycerol-rizinoleat; a second layer, including a water phase layer encapsulating the first layer, the water phase layer including hyaluronic acid, Cu-GHK tripeptide, palmitoyl-KTTKS pentapeptide, and hexapeptide argireline; a third layer, including another oil phase layer encapsulating the second layer; a fourth layer, including another water phase layer encapsulating the third layer; a fifth layer, including another oil phase layer encapsulating the fourth layer; and a sixth layer, including an outmost cream layer encapsulating the fifth layer.

Method for preparing botulinum neurotoxin and nanoparticle thereof are provided. The method includes fermenting bacteria Clostridium botulinum in a fermentation media free of animal-derived ingredients and contacting the fermentation media with an anion exchange media slurry and obtaining a supernatant including the botulinum neurotoxin by centrifugation. The method further includes dialyzing the supernatant and collecting a dialyzed solution including the botulinum neurotoxin, contacting the dialyzed solution with an anion exchange chromatography column, contacting an elute collected from the anion exchange chromatography column with a cation exchange chromatography column, and collecting an elute. The nanoparticle includes multi-layer including an innermost water phase core including biomolecules encapsulated by an oil phase layer, thereby forming a water-in-oil structure, water phase layers; oil phase layers; and an outmost cream layer. The water phase layers and the oil phase layers alternatively encapsulate the water-in-oil structure. The biomolecules include botulinum neurotoxin and/or hyaluronic acid.

Method for preparing botulinum neurotoxin and nanoparticle thereof are provided. The method includes fermenting bacteria Clostridium botulinum in a fermentation media free of animal-derived ingredients and contacting the fermentation media with an anion exchange media slurry and obtaining a supernatant including the botulinum neurotoxin by centrifugation. The method further includes dialyzing the supernatant and collecting a dialyzed solution including the botulinum neurotoxin, contacting the dialyzed solution with an anion exchange chromatography column, contacting an elute collected from the anion exchange chromatography column with a cation exchange chromatography column, and collecting an elute. The nanoparticle includes multi-layer including an innermost water phase core including biomolecules encapsulated by an oil phase layer, thereby forming a water-in-oil structure, water phase layers; oil phase layers; and an outmost cream layer. The water phase layers and the oil phase layers alternatively encapsulate the water-in-oil structure. The biomolecules include botulinum neurotoxin and/or hyaluronic acid.